biostudies-literatureUnknown62Pelaz SGFundación Ramón ArecesMinisterio de Ciencia, Innovación y UniversidadesJunta de Castilla y LeónFundación Científica Asociación Española Contra el Cáncer<h4>Background</h4>Glioblastoma is the most aggressive primary brain tumour and has a very poor prognosis. Inhibition of c-Src activity in glioblastoma stem cells (GSCs, responsible for glioblastoma lethality) and primary glioblastoma cells by the peptide TAT-Cx43_266-283 reduces tumorigenicity, and boosts survival in preclinical models. Because c-Src can modulate cell metabolism and several reports revealed poor clinical efficacy of various antitumoral drugs due to metabolic rewiring in cancer cells, here we explored the inhibition of advantageous GSC metabolic plasticity by the c-Src inhibitor TAT-Cx43_266-283.<h4>Methods</h4>Metabolic impairment induced by the c-Src inhibitor TAT-Cx43_266-283 in vitro was assessed by fluorometry, western blotting, immunofluEBioMedicine103134https://www.ebi.ac.uk/biostudies/studies/S-EPMC7708820biostudies-literatureTargeting metabolic plasticity in glioma stem cells in vitro and in vivo through specific inhibition of c-Src by TAT-Cx43_266-283.PMC7708820Talaveron RTabernero ARamirez de Molina AMedina JMTabernero MAlvarez-Vazquez AJaraiz-Rodriguez MPelaz SGGomez de Cedron MFlores-Hernandez RLillo CGarcia-Vicente LfalseTargeting metabolic plasticity in glioma stem cells in vitro and in vivo through specific inhibition of c-Src by TAT-Cx43_266-283.<h4>Background</h4>Glioblastoma is the most aggressive primary brain tumour and has a very poor prognosis. Inhibition of c-Src activity in glioblastoma stem cells (GSCs, responsible for glioblastoma lethality) and primary glioblastoma cells by the peptide TAT-Cx43_266-283 reduces tumorigenicity, and boosts survival in preclinical models. Because c-Src can modulate cell metabolism and several reports revealed poor clinical efficacy of various antitumoral drugs due to metabolic rewiring in cancer cells, here we explored the inhibition of advantageous GSC metabolic plasticity by the c-Src inhibitor TAT-Cx43_266-283.<h4>Methods</h4>Metabolic impairment induced by the c-Src inhibitor TAT-Cx43_266-283 in vitro was assessed by fluorometry, western blotting, immunoflu2020-01-01T00:00:00Z2020 Dec2026-05-08T15:16:35.904Z2021-02-20T07:37:58ZS-EPMC77088203325402710.1016/j.ebiom.2020.103134